natgillin/translations-raw huggingface dataset:
− fingernail infections, detachment of the nail from the nail bed, boils, widening of small blood vessels, damage to the blood vessels of the skin, allergic inflammation of blood vessels 
− infekcije noktiju, odvajanje noktiju od ležišta, čirevi na koži, proširenje malih krvnih žila,
Male Fertility 
Muška plodnost
Dermatitis and sunburn 
Dermatitis i opekline od sunca
In the event of (prior) treatment with medicinal products that can have adverse reactions on bone marrow (e.g. sulphonamides, trimethoprim/sulphamethoxazole, chloramphenicol, pyrimethamine), the possibility of haematopoietic disorders must be considered. 
sulfonamidi, trimetoprim/sulfametoksazol, kloramfenikol, pirimetamin), mora se uzeti u obzir mogućnost hematopoetskih poremećaja.
− fever, sore throat, flu-like symptoms 
− vrućica, grlobolja, simptomi nalik gripi
− skin rash, skin redness and itching. 
− proljev − kožni osip, crvenilo kože i svrbež.
Following the occurrence of haematemesis, black-coloured stools or blood in the stools, treatment must be discontinued. 
Liječenje se mora prekinuti nakon pojave hematemeze, stolice crne boje ili krvi u stolici.
Depression Mood swings Insomnia 
Psihijatrijski poremećaji depresija promjene raspoloženja nesanica
If you suffer from diarrhoea please speak to your doctor. 
Ako imate proljev, obratite se liječniku.
Ethyl parahydroxybenzoate (E214) Sodium methyl parahydroxybenzoate (E219) Citric acid monohydrate 
6.1 Popis pomoćnih tvari makrogol 400 glicerol okus naranče sukraloza etilparahidroksibenzoat (E214) natrijev metilparahidroksibenzoat (E219) citratna kiselina hidrat trinatrijev citrat pročišćena voda
The prescriber should make sure patients understand that Jylamvo (methotrexate) should only be taken once a week. 
Liječnik koji propisuje lijek mora provjeriti da bolesnici razumiju da se lijek Jylamvo (metotreksat)
Metabolism and nutrition disorders 
Poremećaji metabolizma i prehrane šećerna bolest
Your doctor will tell you what dose you should take for your condition and when you should take the dose. 
Doza u akutnoj limfoblastičnoj leukemiji (ALL) Liječnik će Vam reći koju dozu morate uzimati za svoje stanje te kada je morate uzeti.
− loss of sex drive, erection problems, vaginal discharge, infertility, enlargement of the breasts in men (gynaecomastia) − fever. 
− protein u mokraći − gubitak spolnog nagona, teškoće s erekcijom, iscjedak iz rodnice, neplodnost, povećanje dojki u muškaraca (ginekomastija)
Osteonecrosis of jaw (secondary to lymphoprolifer -ative disorders) 
Osteonekroza čeljusti (uslijed limfoproliferativn
− mood swings 
− promjene raspoloženja
− kidney disease, inflammation or ulcers of the bladder (possibly also with blood in the urine), 
− bolest bubrega, upala ili ranice mokraćnog mjehura (moguća i krv u mokraći), bolno mokrenje
− inflammation of the lungs (pneumonia) with dry cough, shortness of breath and fever 
− glavobolja, umor, ošamućenost − upala pluća (pneumonija) sa suhim kašljem, nedostatkom zraka i vrućicom
5.3 Preclinical safety data 
5.3 Neklinički podaci o sigurnosti primjene Kronična toksičnost
− lung damage 
− oštećenje pluća
Take the medicine pack with you when you visit your doctor or the hospital. 
Kada odlazite liječniku ili u bolnicu, sa sobom ponesite pakiranje lijeka.
Allergic reactions, Anaphylactic shock, 
Poremećaji imunološkog sustava alergijske reakcije,
Cerebral oedema, Acute aseptic meningitis with meningism (paralysis, vomiting), Lethargy, 
akutni aseptički meningitis s meningizmom (paraliza,
Put on disposable gloves before handling. 
Prije rukovanja navucite jednokratne rukavice.
Particularly in the case of orthopaedic surgery where the risk of infection is high, combination therapy with methotrexate and immunomodulatory medicinal products must be used with caution. 
Osobito u slučaju ortopedskih kirurških zahvata pri kojima postoji visoki rizik od infekcije,
Data from a randomised trial in patients with juvenile rheumatoid arthritis (aged 2.8 to 15.1 years) indicated greater oral bioavailability of methotrexate in the fasting state. 
Podaci iz randomiziranog ispitivanja u bolesnika s juvenilnim reumatoidnim artritisom (u dobi od 2,8
Especially strict monitoring of the patient is indicated following prior radiotherapy (especially of the pelvis), functional impairment of the haematopoietic system (e.g., following prior radio- or chemotherapy), impaired general condition as well as advanced age and in very young children. 
Posebno strogo praćenje bolesnika indicirano je nakon prethodne radioterapije (osobito zdjelice),
− low blood pressure, blood clots 
− nizak krvni tlak, krvni ugrušci − upala krajnika, prekid disanja, astma
shingles [herpes zoster]) as they may flare up - if you have ever had any liver or kidney disease - if you have problems with your lung function - if you are particularly overweight - if you have an abnormal build-up of fluid in the abdomen (ascites) or around the lungs (pleural effusions) - if you are dried out (dehydrated) or suffer from conditions that result in dehydration (vomiting, 
− ako imate abnormalno nakupljanje tekućina u području trbuha (ascites) ili oko pluća (pleuralna efuzija) − ako Vam nedostaje vode u tijelu (dehidrirani ste) ili bolujete od stanja koja za posljedicu imaju dehidraciju (povraćanje, proljev, zatvor, upala sluznice usta).
Methotrexate is a powerful human teratogen, with an increased risk of spontaneous abortions, intrauterine growth restriction and congenital malformations in case of exposure during pregnancy. 
zastoja intrauterinog rasta i urođenih malformacija u slučaju izlaganja tijekom trudnoće.
− diarrhoea 
− sedative
The occurrence and severity of adverse reactions depend on dosage level and frequency of administration of methotrexate. 
Pojava i težina nuspojava ovise o dozi i učestalosti primjene metotreksata.
− inflammation of the pancreas, inflammation of the digestive tract, bloody stools, inflamed gums, 
− upala gušterače, upala probavnog sustava, krvave stolice, upaljene desni, probavne smetnje
For arthritis and psoriasis take only once a week on …………. 
Za liječenje artritisa i psorijaze uzimati samo jednom tjedno u ………………(navesti puni naziv dana u tjednu kada se lijek uzima).
Telangiectasis, Hidradenitis 
akutna paronihija, furunkuloza, teleangiektazija, hidradenitis
Thromboembolic reactions (including arterial and cerebral thrombosis, thrombophlebitis, deep leg vein thrombosis, retinal vein thrombosis, pulmonary embolism), Hypotension 
(uključujući arterijsku i cerbralnu trombozu, tromboflebitis, trombozu dubokih vena nogu, trombozu vena mrežnice,
Pruritus vasculitis, herpetiform skin eruptions, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome), Increased rheumatic nodules, 
toksična epidermalna nekroliza (Lyellov sindrom), povećanje broja reumatoidnih čvorića,
How to store Jylamvo 
Moguće nuspojave Kako čuvati Jylamvo
The dose should be adjusted as follows for patients with rheumatoid arthritis, juvenile arthritis, psoriasis and psoriatic arthritis. 
U bolesnika s reumatoidnim artritisom, juvenilnim artritisom, psorijazom i psorijatičnim artritisom dozu treba prilagoditi kako je prikazano u nastavku.
Men should not donate semen during therapy or for 6 months following discontinuation of methotrexate. 
Muškarci ne smiju donirati sjeme tijekom liječenja i tijekom
Pulmonary fibrosis 
AUC metabolita
Petechiae, Bruising, Erythema multiforme, Cutaneous erythematous eruptions, Lesions of psoriasis may worsen with concomitant UV therapy, Radiation dermatitis and sunburn may be “recalled” 
psorijatične lezije mogu se pogoršati uz istodobnu UV terapiju, radijacijski dermatitis i opekline od sunca mogu se pojaviti kao “odzivna reakcija”
Push the tip of the dosing syringe into the hole in the adaptor. 
Vrh štrcaljke za doziranje gurnite u otvor nastavka za bočicu.
Megaloblastic anaemia 
aplastična anemija,
However, a risk cannot be completely excluded and there is no information regarding higher methotrexate doses. 
Međutim, rizik se ne može u potpunosti isključiti.
Concomitant therapy with medicinal products that can cause folic acid deficiency (e.g. sulphonamides, trimethoprim/sulphamethoxazole) can result in increased methotrexate toxicity. 
Istodobna terapija lijekovima koji mogu prouzročiti nedostatak folatne kiseline (npr. sulfonamidi,
• Concurrent vaccination with live vaccines 
• istodobno cijepljenje živim cjepivima.
Dose reduction should be considered in elderly patients (65 years and over) due to reduced liver and kidney function as well as low folic acid reserves which occur with increased age. 
Zbog slabije funkcije jetre i bubrega te niskih rezervi folatne kiseline koje se javljaju s uznapredovalom dobi, u starijih bolesnika (65 godina i stariji) treba razmotriti smanjenje doze.
Methotrexate should be administered only with the greatest caution, if at all, in patients with significant existing or previous liver disease, especially if due to alcohol. 
U bolesnika sa značajnom postojećom ili prethodnom bolešću jetre, a osobito ako je prouzročena alkoholom, metotreksat, ako uopće, treba primjenjivati samo s najvećim oprezom.
Pain, 
zimica,
Doses exceeding 20 mg (10 ml)/week can be associated with a substantial increase in toxicity, 
Doze veće od 20 mg (10 ml) tjedno mogu se povezati sa značajnim povećanjem toksičnosti, osobito s depresijom koštane srži.
Dosage in adult rheumatoid arthritis: The usual initial dose is 7.5 mg (3.75 ml), once a week. 
Uobičajena početna doza je 7,5 mg (3,75 ml) jednom tjedno.
Pericarditis, Pericardial effusion, Pericardial tamponade 
Srčani poremećaji perikarditis, perikardijalna efuzija, perikardijalna tamponada
If you had skin problems after radiotherapy (radiation dermatitis) or sunburn, these reactions can recur after methotrexate therapy (recall reaction). 
Ako imate problema s kožom nakon terapije zračenjem (radijacijski dermatitis) ili opekline od sunca,
This oral solution contains 2 mg methotrexate in 1 ml solution and the scaling of the dosing syringe is in ml and not mg. 
Upozorenja i mjere opreza Važno upozorenje o dozi lijeka Jylamvo (metotreksata): Ova oralna otopina sadrži 2 mg metotreksata u 1 ml otopine, a mjerne oznake na dozirnoj štrcaljki odnose se na ml, a ne na mg.
You and your partner should avoid having a baby if you are being given methotrexate at the time and for at least 6 months after the end of your treatment with methotrexate. 
Ako primate metotreksat, Vi i partner/partnerica morate izbjegavati trudnoću tijekom liječenja i još najmanje 6 mjeseci nakon završetka liječenja metotreksatom.
Aplastic anaemia, Lymphoproliferative disorder2, 
limfoproliferativni poremećaj2,
Closer monitoring of liver enzymes should be undertaken in patients taking other hepatotoxic medicinal products concomitantly (e.g. leflunomide). 
U bolesnika koji istodobno uzimaju druge hepatotoksične lijekove (npr. leflunomid), potrebno je pažljivije praćenje jetrenih enzima.
Oral solution. 
Citotoksično.
− inflammation and ulcers of the vagina. 
− upala i ranice u rodnici.
Photosensitivity, Increased skin pigmentation, Hair loss, Impaired wound healing, 
povećana pigmentacija kože, gubitak kose, narušeno cijeljenje rana, urtikarija nastanak modrica, multiformni eritem, kožne eritematozne erupcije,
(include weekday of intake in full). 
(uključujući redovne laboratorijske testove).
Take Jylamvo only once a week for the treatment of rheumatic or skin diseases (RA, JIA and psoriasis or psoriatic arthritis). 
Za liječenje reumatskih ili kožnih bolesti (reumatoidni artritis, juvenilni idiopatski artritis i psorijaza ili psorijatični artritis), uzmite Jylamvo samo jedanput tjedno.
Proteinuria 
hematemeza
− bone fractures 
− lomovi kostiju
− mouth ulcers 
I PSORIJAZE.
Jylamvo is a medicine that: - suppresses the growth of certain cells in the body that multiply rapidly (an anticancer medicine) - reduces unwanted reactions by the body's own defense mechanisms (an immunosuppressive agent) - has an anti-inflammatory effect 
− smanjuje neželjene reakcije obrambenog sustava tijela (imunosupresivni lijek)
Vaginal 
Jylamvo.
Dose in rheumatic and skin diseases (RA, JIA and psoriasis or psoriatic arthritis) 
Doza u reumatskim i kožnim bolestima (reumatoidni artritis, juvenilni idiopatski artritis i psorijaza ili psorijatični artritis) Jylamvo uzimajte samo jedanput tjedno.
Immunosuppression, Allergic vasculitis (severe toxic symptom), Hypogammaglobulinaemia 
imunosupresija, alergijski vaskulitis
Diabetes mellitus 
− šećerna bolest
Neoplasms benign, malignant and unspecified (including cysts and polyps) 
Dobroćudne, zloćudne i nespecificiran e novotvorine
Certain brain disorders (encephalopathy/leukoencephalopathy) have been reported in cancer patients receiving methotrexate. 
U bolesnika s rakom koji primaju metotreksat, zabilježeni su neki poremećaji mozga
Erythema, Exanthema, 
eritemom i pruritusom.
Highly proliferating tissue such as malignant cells, bone marrow, foetal cells, skin epithelium and mucosa is generally more sensitive to this effect of methotrexate. 
Na taj učinak metotreksata uglavnom su osjetljivija tkiva koja brzo proliferiraju kao što su zloćudne stanice, koštana srž, fetalne stanice, kožni epitel i sluznica.
Nephropathy Inflammation and ulceration of urinary bladder (possibly with haematuria), Dysuria 
Poremećaji bubrega i mokraćnog sustava nefropatija, upala i ulceracija mokraćnog mjehura (moguće s hematurijom), dizurija zatajenje bubrega, oligurija, anurija, azotemija proteinurija
Side effects affecting the central nervous system such as tiredness or dizziness can occur during treatment with Jylamvo. 
Tijekom liječenja lijekom Jylamvo mogu nastati nuspojave koje zahvaćaju središnji živčani sustav, kao što su umor ili omaglica.
It is particularly important to tell your doctor if you are using the following medicines: - other medicines for rheumatoid arthritis or psoriasis, such as leflunomide, azathioprine (also used to prevent rejection after an organ transplant), sulfasalazine (also used for ulcerative colitis) - ciclosporin (for supressing the immune system) - non-steroidal anti-inflammatory drugs or salicylates (medicines against pain and/or inflammation such as acetylsalicylic acid, diclofenac and ibuprofen or pyrazole) - live vaccines 
− nesteroidne protuupalne lijekove ili salicilate (lijekove protiv bolova i/ili upale kao što su acetilsalicilatna kiselina, diklofenak i ibuprofen ili pirazol)
Oral use 
PRIMJENU
Hepatic impairment 
− živa cjepiva
If methotrexate comes into contact with skin or mucosa, it should be washed immediately and thoroughly with soap and water. 
treba ga odmah temeljito oprati sapunom i vodom.
This summary was last updated in 11-2016. 
Sažetak je posljednji put ažuriran: 11. 2016.
The medicine is available as tablets (15, 30 and 45 mg) and the recommended starting dose is 15 or 30 mg once a day. 
Lijek je dostupan u obliku tableta (15, 30 i 45 mg), a preporučena početna doza je 15 ili 30 mg jedanput dnevno.
This means that Pioglitazone Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos. 
To znači da je Pioglitazone Accord sličan „referentnom lijeku” koji je već odobren u Europskoj uniji (EU) pod nazivom Actos.
The full EPAR for Pioglitazone Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Cjelovito europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za lijek Pioglitazone Accord nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Pioglitazone Accord pioglitazone 
Pioglitazone Accord pioglitazon
As a consequence, the blood glucose levels are reduced and this helps to control type 2 diabetes. 
Posljedica toga je smanjenje razine glukoze u krvi, što pomaže pri kontroli dijabetesa tipa 2.
Pioglitazone Accord is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight. 
Lijek Pioglitazone Accord primjenjuje se za liječenje dijabetesa tipa 2 u odraslih osoba (u dobi od 18 godina i starijih), osobito u onih prekomjerne tjelesne težine.
The active substance in Pioglitazone Accord, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces. 
Djelatna tvar u lijeku Pioglitazone Accord, pioglitazon, čini stanice (masti, mišića i jetre) osjetljivijima na inzulin, što znači da tijelo bolje iskorištava inzulin koji proizvodi.
The European Commission granted a marketing authorisation valid throughout the European Union for Pioglitazone Accord on 21 March 2012. 
Europska komisija izdala je odobrenje za stavljanje lijeka Pioglitazone Accord u promet koje vrijedi na prostoru Europske unije od 21. ožujka 2012.
The company that markets Pioglitazone Accord will produce educational material for doctors prescribing the medicine, which will cover the possible risk of heart failure and bladder cancer with treatments that contain pioglitazone, the criteria for selecting patients and the need to review treatment regularly and stop treatment if patients are no longer benefiting. 
Tvrtka koja stavlja na tržište lijek Pioglitazone Accord osigurat će edukativni materijal za liječnike koji propisuju taj lijek koji će obuhvaćati informacije o mogućem riziku od srčanog zastoja i raka mjehura u liječenjima u kojima se primjenjuje pioglitazon, o kriterijima za odabir bolesnika te potrebi za redovitim procjenjivanjem učinaka terapije i prekidom liječenja ako bolesnici više nemaju koristi od njega.
Pioglitazone Accord is a ‘generic medicine'. 
Pioglitazone Accord je „generički lijek”.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pioglitazone Accord has been shown to have comparable quality and to be bioequivalent to Actos. 
Odbor za lijekove za humanu uporabu(CHMP) pri Agenciji zaključio je kako je, u skladu sa zahtjevima EU-a, lijek Pioglitazone Accord dokazao usporedivu kakvoću te da je bioekvivalentan lijeku Actos.
What measures are being taken to ensure the safe and effective use of Pioglitazone Accord? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Pioglitazone Accord?
Therefore, the CHMP's view was that, as for Actos, the benefit outweighs the identified risk. 
Stoga je stav CHMP-a da korist nadmašuje identificirani rizik, kao i za Actos.
What is Pioglitazone Accord and what is it used for? 
Što je Pioglitazone Accord i za što se koristi?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pioglitazone Accord have also been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Pioglitazone Accord nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
It is not intended to provide practical advice on how to use Pioglitazone Accord. 
Svrha sažetka nije davati praktične savjete o primjeni lijeka Pioglitazone Accord.
This is a summary of the European public assessment report (EPAR) for Pioglitazone Accord. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) za lijek Pioglitazone Accord.
Treatment with Pioglitazone Accord should be reviewed after three to six months, and discontinued in patients who are not deriving sufficient benefit. 
Nakon tri do šest mjeseci liječenja lijekom Pioglitazone Accord potrebno je procijeniti učinke liječenja i prekinuti ga u bolesnika u kojih nisu vidljive dostatne koristi.
Because Pioglitazone Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Budući da je lijek Pioglitazone Accord generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i kod referentnog lijeka.
Other information about Pioglitazone Accord 
Ostale informacije o lijeku Pioglitazone Accord
What are the benefits and risks of Pioglitazone Accord? 
Koje su koristi i rizici lijeka Pioglitazone Accord?
For more information about treatment with Pioglitazone Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o liječenju lijekom Pioglitazone Accord pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
The Committee recommended that Pioglitazone Accord be approved for use in the EU. 
Odbor je preporučio davanje odobrenja za stavljanje lijeka Pioglitazone Accord u promet u EU-u.
Pioglitazone Accord can only be obtained with a prescription. 
Lijek Pioglitazone Accord izdaje se samo na recept.
• in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of diabetes medicine) when metformin is not suitable in patients who are not satisfactorily controlled on a sulphonylurea alone; 
• u kombinaciji s metforminom u bolesnika u kojih se ne može postići zadovoljavajuća kontrola samo metforminom, ili sulfonilurejom (drugom vrstom lijeka za liječenje dijabetesa) ako metformin nije prikladan u bolesnika koji se ne mogu zadovoljavajuće kontrolirati samo sulfonilurejom;
• on its own in patients for whom metformin (another diabetes medicine) is not suitable. 
• kao monoterapija u bolesnika kojima metformin (drugi lijek za liječenje dijabetesa) nije prikladan;
Pioglitazone Accord contains the active substance pioglitazone. 
Pioglitazone Accord sadrži djelatnu tvar pioglitazon.
Because Pioglitazone Accord is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos. 
Budući da je lijek Pioglitazone Accord generički lijek, ispitivanja na ljudima bila su ograničena na utvrđivanje činjenice je li lijek bioekvivalentan referentnom lijeku Actos.
For practical information about using Pioglitazone Accord, patients should read the package leaflet or contact their doctor or pharmacist. 
Praktične informacije o primjeni lijeka Pioglitazone Accord bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
Why is Pioglitazone Accord approved? 
Zašto je lijek Pioglitazone Accord odobren?
How does Pioglitazone Accord work? 
Kako djeluje Pioglitazone Accord?
How has Pioglitazone Accord been studied? 
Kako je Pioglitazone Accord ispitivan?
How is Pioglitazone Accord used? 
Kako se Pioglitazone Accord koristi?
What is Opsumit and what is it used for? 
Što je Opsumit i za što se koristi?
This overview was last updated in 07-2018. 
Ovaj pregled informacija posljednji je put ažuriran u 07. 2018.
Women should also not become pregnant for one month after stopping treatment. 
Žene ne smiju zatrudnjeti mjesec dana nakon prekida liječenja.
What measures are being taken to ensure the safe and effective use of Opsumit? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Opsumit?
The medicine is available as 10 mg tablets and taken at a dose of one tablet every day. 
Lijek je dostupan u obliku tableta od 10 mg, a primjenjuje se u dozi od jedne tablete jedanput dnevno.
In animal studies, Opsumit was shown to have an adverse effect on the development of embryos. 
U ispitivanjima na životinjama dokazano je da Opsumit ima štetan učinak na razvoj embrija.
These are part of a natural mechanism in the body that can cause arteries to narrow. 
To su dijelovi prirodnog mehanizma u tijelu koji mogu uzrokovati suženje arterija.
The most common side effects with Opsumit (which may affect more than 1 in 10 people) include nasopharyngitis (inflammation of the nose and throat), anaemia (low red blood cell counts) and headache. 
Najčešće nuspojave lijeka Opsumit (koje se mogu javiti u više od 1 na 10 osoba) jesu nazofaringitis (upala nosa i grla), anemija (nizak broj crvenih krvnih stanica) i glavobolja.